Antibody treatments of inflammatory arthritis.

Abstract

Inflammatory arthropathies such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis are extremely common in the community, with a prevalence of up to 5%, and they cause substantial morbidity. The development of anti-TNF agents for use initially in rheumatoid arthritis, and subsequently more broadly in inflammatory arthritis, represents the biggest advance in management of these conditions since the introduction of corticosteroid agents, and is a major vindication of public funded arthritis research. However, there are limitations of even these highly effective agents. A significant minority of patients with inflammatory arthritis do not respond to these anti-TNF agents, they are associated with substantial risk of toxicity, require parenteral administration, and are extremely expensive. New antibody treatments in development can be divided into anti-cytokine agents, cell-targeted therapies, co-stimulation inhibitors, and treatments aimed at preventing joint erosion consequent on inflammation. This review discusses the state of the art in the development of these agents for management of this common group of diseases.

• Authors: Matthew A Brown
• Journal: Current medicinal chemistry (Curr Med Chem) Vol. 12 Issue 25 Pg. 2943-6 ( 2005) ISSN: 0929-8673 [Print] United Arab Emirates
• PMID: 16378497 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Inflammatory Agents
• Antibodies
• Cytokines

Topics

• Anti-Inflammatory Agents (therapeutic use)
• Antibodies (therapeutic use)
• Arthritis (drug therapy, immunology)
• B-Lymphocytes (drug effects, immunology)
• Cytokines (antagonists & inhibitors)
• Humans
• Inflammation (drug therapy, immunology)
• Osteoporosis (drug therapy)
• T-Lymphocytes (drug effects, immunology)